Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial

• Published in: The New England journal of medicine Vol. 389; no. 6; pp. 514 - 526
• Main Authors: Jastreboff, Ania M., Kaplan, Lee M., Frías, Juan P., Wu, Qiwei, Du, Yu, Gurbuz, Sirel, Coskun, Tamer, Haupt, Axel, Milicevic, Zvonko, Hartman, Mark L.
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 10.08.2023
• Subjects: Adult; Agonists; Anti-Obesity Agents - administration & dosage; Anti-Obesity Agents - adverse effects; Anti-Obesity Agents - pharmacology; Anti-Obesity Agents - therapeutic use; Body Mass Index; Body weight; Clinical Medicine; Clinical Medicine General; Confidence intervals; Diabetes; Diet; Double-Blind Method; Drug therapy; Endocrinology; Female; Gastric Inhibitory Polypeptide - agonists; Gastroenterology; GIP protein; Glucagon; Glucagon-like peptide 1; Glucagon-Like Peptide 1 - agonists; Heart rate; Humans; Injections, Subcutaneous; Male; Nutrition; Obesity; Obesity - complications; Obesity - drug therapy; Peptides; Placebos; Receptors, Glucagon - agonists; Statistical analysis; Treatment Outcome; Weight control; Weight Loss - drug effects; United States > US

Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors. Its dose-response relationships with respect to side effects, safety, and efficacy for the treatment of obesity are not known. We conducted a phase 2, double-bl...